These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 7565956)
41. [Indications and successes of conservative therapy in gastroenterology: peptic ulcer]. Gugler R Z Gastroenterol Verh; 1989 Jul; 24():82-4. PubMed ID: 2474995 [No Abstract] [Full Text] [Related]
42. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Sontag SJ Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703 [TBL] [Abstract][Full Text] [Related]
43. [Therapy of peptic ulcer. H2 receptor blockers]. Domschke W Verh Dtsch Ges Inn Med; 1988; 94():272-5. PubMed ID: 2905101 [No Abstract] [Full Text] [Related]
44. Medical therapy of extraesophageal gastroesophageal reflux disease. Katz PO J Clin Gastroenterol; 2000 Apr; 30(3 Suppl):S42-4. PubMed ID: 10777172 [TBL] [Abstract][Full Text] [Related]
45. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis. Dutch Esophagitis Study Group. Wesdorp IC; Dekker W; Festen HP Clin Ther; 1997; 19(5):1048-57. PubMed ID: 9385492 [TBL] [Abstract][Full Text] [Related]
46. Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis. Adachi K; Komazawa Y; Mihara T; Fujishiro H; Ishihara S; Amano Y; Kinoshita Y J Clin Gastroenterol; 2004 Mar; 38(3):297-8. PubMed ID: 15128081 [No Abstract] [Full Text] [Related]
47. [Gastroduodenal ulcer--changes in surgical therapy by long-term drug treatment]. Peitsch W Zentralbl Chir; 1986; 111(23):1433-40. PubMed ID: 2881413 [TBL] [Abstract][Full Text] [Related]
48. Healing, relapse rates and prophylaxis of reflux esophagitis. Glise H Scand J Gastroenterol Suppl; 1989; 156():57-64. PubMed ID: 2568016 [TBL] [Abstract][Full Text] [Related]
51. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Harris RA; Kuppermann M; Richter JE Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748 [TBL] [Abstract][Full Text] [Related]
52. Treatment of gastroesophageal reflux: the role of proton pump inhibitors. Schulman MI; Orlando RC Adv Intern Med; 1995; 40():273-302. PubMed ID: 7747649 [No Abstract] [Full Text] [Related]
54. [Guidelines for good practice: anti-ulcer agents, indications in the adult. French Agency for Health Safety of Health Products]. Therapie; 1999; 54(5):509-17. PubMed ID: 10667082 [No Abstract] [Full Text] [Related]
55. Medical management of esophageal reflux. Hirschowitz BI Yale J Biol Med; 1994; 67(3-4):223-31. PubMed ID: 7502531 [TBL] [Abstract][Full Text] [Related]
56. [Clinical aspects of Kvamatel (famotidine) administration]. Golochevskaia VS Klin Med (Mosk); 1996; 74(1):45-7. PubMed ID: 8649009 [No Abstract] [Full Text] [Related]
57. Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis. Pace F; Maconi G; Molteni P; Minguzzi M; Bianchi Porro G Scand J Gastroenterol; 1995 Feb; 30(2):101-5. PubMed ID: 7732329 [TBL] [Abstract][Full Text] [Related]
58. Over the counter sales of histamine-2 receptor antagonists. Petersen H Scand J Gastroenterol Suppl; 1988; 155():20-2. PubMed ID: 2907682 [TBL] [Abstract][Full Text] [Related]
59. Treatment of severe reflux esophagitis. Richter JE Ann Intern Med; 1986 Apr; 104(4):588-9. PubMed ID: 2869728 [No Abstract] [Full Text] [Related]
60. Is body mass index really the most important factor determining the healing of reflux esophagitis by esomeprazole? Lo GH Am J Gastroenterol; 2009 Mar; 104(3):787; author reply 787-8. PubMed ID: 19240701 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]